このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy (DiabPueblo)

2021年9月2日 更新者:Sansum Diabetes Research Institute

Diabetes Pueblo Program - The Application and Acceptability of Culturally Appropriate Education Programs for Current or Potential Insulin Therapy Users With Type 2 Diabetes in the Latino Community

Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers, such as socioeconomic and cultural factors, to starting and optimizing therapies, including insulin. Latinos have cultural beliefs and behaviors specific to this population that should be appropriately addressed in a diabetes self-management education and support program. Diabetes Pueblo is a diabetes education program that may be a solution to help address the barriers Latinos with T2D have to diabetes care and insulin use. The Diabetes Pueblo program consists of two targeted diabetes education curriculums for the local Latino community: (a) Diabetes Fundamentals and (b) Insulin Success, a culturally appropriate program course addressing barriers to initiating and optimizing insulin and T2D therapies. We will explore if Diabetes Pueblo Program improves knowledge of lifestyle advice for healthy eating and physical activity, increase the propensity to use insulin when clinically indicated, and improve success rates with insulin therapy by addressing common fears and negative perceptions of T2D therapies in this population.

調査の概要

状態

完了

条件

詳細な説明

Diabetes mellitus (DM) is a group of chronic disorders typified by raised blood glucose levels. An estimated 30 million people in the United States (US) (9.4% of the population) have diabetes. Type 1 diabetes (T1D) is defined by a rapid onset, often in childhood, and insulin dependence; while type 2 diabetes (T2D) is considered to have a slow onset and insulin insensitivity. Insulin is a required form of treatment for all T1D, and T2D patients who cannot achieve glycemic control through exercise and diet or other medications alone. Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers to starting and optimizing therapies, including insulin. Barriers include socioeconomic and cultural factors, as well as inadequate encouragement from health care providers. There are also challenges associated with access to timely and appropriate diabetes education. Some of these barriers may improve by using trained community health workers from the Latino community, as there is evidence that they are effective in supporting adherence and persistence with therapies (including insulin) and in encouraging lifestyle changes for T2D patients within their own communities.

The 2017 National Standards of Care for Diabetes Self-Management Education and Support (DSME/S) outline quality, evidenced based guidelines for DSME/S programs and guide those who will be providing these services. Benefits of DSME/S programs include improved clinical outcomes such as HbA1c and quality of life while reducing hospitalizations and health care costs. Hispanics are known to have a higher prevalence of diabetes, but use of DSME/S programs are vastly underutilized which means that many individuals in the Latino community with T2D are likely not receiving critical DSME/S services. It is crucial that DSME/S services be aligned with the needs of the target population in order to increase adherence and improve health outcomes. Latinos have cultural beliefs and behaviors specific to this population that should be appropriately addressed in a DSME/S program.

Diabetes Pueblo is a diabetes education program that may be a solution to help address the barriers Latinos with T2D have to diabetes care and insulin use. The Diabetes Pueblo program consists of two targeted diabetes education curriculums for the local Latino community: (a) Diabetes Fundamentals and (b) Insulin Success, a culturally appropriate program course addressing barriers to initiating and optimizing insulin and T2D therapies. Trained community health workers, also known as promotores, will deliver both programs. Ultimately, we will explore if Diabetes Pueblo Program improves knowledge of lifestyle advice for healthy eating and physical activity, increase the propensity to use insulin when clinically indicated, and improve success rates with insulin therapy by addressing common fears and negative perceptions of T2D therapies in this population.

This is a prospective pilot study. The Diabetes Pueblo program applied in this study is one program that consists of two newly created, targeted education curriculums for T2D Latino adults delivered over the course of 11 weeks by designated promotores, community health workers, to approximately 20 study participants at Sansum Diabetes Research Institute.

研究の種類

介入

入学 (実際)

25

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Santa Barbara、California、アメリカ、93463
        • Sansum Diabetes Research Institute

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Individuals > 18 years of age
  2. Self-reported Latino heritage
  3. Fluent in Spanish
  4. Type 2 diabetes diagnosis
  5. Available to attend the educational series and all study visits
  6. Willingness to have height, weight, waist circumference, and HbA1c measured before and after the educational course
  7. Individuals with poor glycemic control, as defined by the following:

    • HbA1c ≥ 8% at or prior to enrollment assessment (most recent lab within 3 months or provided at Sansum Diabetes Research Institute (SDRI) screening visit),

    OR

    • HbA1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):

      • Fasting plasma glucose ≥ 130 mg/dL
      • 2-hour post-prandial or random blood glucose ≥ 180 mg/dL
      • ≥1 hypoglycemic event (blood glucose < 70 mg/dL)

    OR

    • Individuals new to insulin or being considered for insulin therapy by their healthcare provider
  8. Willing and able to provide consent to take part in the study
  9. Based on the research staff's judgment, participant must have a good understanding, ability, and willingness to adhere to the protocol

Exclusion Criteria:

  1. Has a cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the education program language that, in the opinion of the screener, would interfere with the ability to provide consent and participate/complete the program
  2. Participation in other studies involving medications or device within 3 months prior to Visit 1
  3. Known or suspected abuse of alcohol, narcotics, or illicit drugs
  4. Current use of insulin pump
  5. For females: Pregnancy or positive pregnancy test
  6. Pharmaceutical employees or those employed in a position where they have a direct role in treating participants with diabetes.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Latino adults with type 2 diabetes

Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -

  1. hemoglobin A1c > 8% at or prior to enrollment, or
  2. hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):

    • Fasting plasma glucose > 130 mg/dL
    • 2-hour post-prandial or random blood glucose > 180 mg/dL
    • > 1 hypoglycemic event (blood glucose < 70 mg/dL) , or
  3. adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider.
These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.
時間枠:11 weeks
The Diabetes Pueblo program consists of two newly created, targeted education curriculums, Diabetes Fundamentals and Insulin Success, for Latino adults with type 2 diabetes. It will be delivered over the course of 11 weeks by designated promotores, community health workers, to approximately 20 study participants at Sansum Diabetes Research Institute.
11 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Diabetes self management evaluated by questionnaire
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class
The Diabetes Self-Management Questionnaire consists of 16 questions to evaluate diabetes self-care including glucose management, dietary control, physical activity, and health-care use. Questions are rated on a 4 point scale - 0 Does not apply to me, 1 Applies to me to some degree, 2 Applies to me to a considerable degree, 3 Applies to me very much. This yields an overall rating of self-care with higher scores indicating more effective diabetes self-care.
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class
Insulin treatment evaluated by questionnaire
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
The Insulin Treatment Appraisal Scale is a validated 20-item questionnaire that will be used in insulin naïve and insulin-treated patients with type 2 diabetes to assess positive and negative perceptions regarding insulin treatment. Items are rated on a 5-point scale ("strongly disagree" to "strongly agree") and the mean of individual item scores is calculated to obtain a total score, with lower scores indicating less negative perceptions regarding insulin treatment.
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Participant evaluation of Diabetes Pueblo evaluated by questionnaire
時間枠:Class 4, week 4; Class 8, week 8; Class 10, week 10
The first questionnaire includes curriculum content questions which are specific to courses 1-4, 5-8, and 9-10.
Class 4, week 4; Class 8, week 8; Class 10, week 10
Participant evaluation of Diabetes Pueblo evaluated by questionnaire
時間枠:Class 11, week 11
The second questionnaire assesses overall program feedback on the entire program.
Class 11, week 11

その他の成果指標

結果測定
メジャーの説明
時間枠
Fingerstick for evaluation of HbA1c related to diabetes
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
HbA1c % will measured in a capillary fingerstick blood sample
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Height measured by Physical exam
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Height measured in centimeters or inches by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Weight measured by Physical exam
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Weight measured in kilograms or pounds by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Waist circumference measured by Physical exam
時間枠:Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Waist circumference measured in centimeters or inches by physical exam
Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class
Socio-demographics assessed by questionnaire
時間枠:Visit 1, week 0 Screening
Socio-demographics measured by questionnaire - including age, gender, self-identified race/ethnicity, contact information, education, occupation, preferred language, insurance status, influenza & pneumonia immunization status, alcohol & tobacco use, birth place, physical activity, food security, and mobile phone use.
Visit 1, week 0 Screening
Foot examination evaluated by Questions
時間枠:Visit 1, week 0 Screening
Foot examination with 'yes or no' and frequency questions
Visit 1, week 0 Screening
Neuropathy Questions
時間枠:Visit 1, week 0 Screening
Questions about neuropathy
Visit 1, week 0 Screening
Retinopathy Questions
時間枠:Visit 1, week 0 Screening
Questions about retinopathy and eye exams
Visit 1, week 0 Screening
Nephropathy Questions
時間枠:Visit 1, week 0 Screening
Questions about nephropathy
Visit 1, week 0 Screening
Medical history and medication status and history assessed by questionnaire
時間枠:Visit 1, week 0 Screening
Medical history, including date of diabetes diagnosis, type of diabetes, diabetes education, diabetes self-care, depression and stress, falls, physician visits, hospital and emergency room visits, and current medications verified by visual inspection and medication history assessed by interview questionnaire
Visit 1, week 0 Screening
Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire
時間枠:Visit 1, week 0 Screening
Menopausal status, pregnancy status (number of live births, number of stillbirths, birthweights of live births, and any diagnosis of type 1 diabetes), and gestational diabetes history for female participants will be determined by questionnaire
Visit 1, week 0 Screening

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jamie Creason, RD、Sansum Diabetes Research Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年5月10日

一次修了 (実際)

2020年2月25日

研究の完了 (実際)

2020年2月25日

試験登録日

最初に提出

2019年7月9日

QC基準を満たした最初の提出物

2019年7月9日

最初の投稿 (実際)

2019年7月11日

学習記録の更新

投稿された最後の更新 (実際)

2021年9月5日

QC基準を満たした最後の更新が送信されました

2021年9月2日

最終確認日

2021年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する